French Firm Synt:em Gains New Financing From Venture Backers | GenomeWeb

NÎMES--Synt:em here, a drug discovery company that specializes in research tools and services for peptide synthesis and contract research for the design and synthesis of new therapeutic molecules, has completed a new round of financing that brought in approximately $3.4 million. The firm is now supported by two venture companies, Apax Partners and Banexi Ventures, and is capitalized with more than $4.25 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.